BeOne Medicines (ONC) Finished Goods (2017 - 2026)

BeOne Medicines (ONC) posted quarterly Finished Goods of $298.2 million for Q1 2026, up 19.57% quarter-over-quarter from $249.4 million in Q4 2025.

BeOne Medicines (ONC) Finished Goods (2017 - 2026) Analysis & Trends

BeOne Medicines (ONC) has reported Finished Goods for 5 consecutive years, with $298.2 million the latest figure, recorded in Q1 2026.

In Q1 2026, Finished Goods changed N/A year-over-year to $298.2 million; the TTM figure through Mar 2026 stood at $298.2 million (changed N/A YoY), while the FY2025 annual figure was $249.4 million, down 5.65% from the prior year.
Finished Goods improved to $298.2 million in Q1 2026 per ONC's latest filing, from $249.4 million in the prior quarter.
Across five years, Finished Goods topped out at $298.2 million in Q1 2026 and bottomed at $249.4 million in Q4 2025.
Historically, Finished Goods has averaged $270.6 million across 3 years, with a median of $264.3 million in 2024.
On a YoY basis, Finished Goods climbed as much as 5.65% in 2025 and fell as far as 5.65% in 2025.
BeOne Medicines' Finished Goods stood at $264.3 million in 2024, then dropped by 5.65% to $249.4 million in 2025, then climbed by 19.57% to $298.2 million in 2026.
Business Quant data shows ONC's Finished Goods at $298.2 million in Q1 2026, $249.4 million in Q4 2025, and $264.3 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn

Download Data